My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.936 +0.616 (+26.53%)
Streaming Delayed Price Updated: 11:49 AM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
37 38 Next >
Outset Medical, SMART Global And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
From Cassava Sciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Why Shares of Cassava Sciences Soared This Week
Cassava bounced back from hitting a 52-week low to start the week. 
Via The Motley Fool
Why Cassava Sciences Stock Is Trading Down Today
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday. 
Via Benzinga
Why Shares of Cassava Sciences Are Dropping Wednesday
The company announced phase 3 trial results for its lead Alzheimer's therapy. 
Via The Motley Fool
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
CEO to Present on Wednesday, October 11th, at 10:30am ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
The 7 Best Meme Stocks to Buy Now: September 2023
Consider these seven past and present faves of the Reddit set to be the best meme stocks to buy this month. 
Via InvestorPlace
Jim Cramer Says No To This Fintech Titan With Declining Margins: 'I Think It's A Value Trap'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ONEOK, Inc's (NYSE: OKE) management is terrific. "The CFO Walter Hulse is like you and me, a Jersey-ite. 
Via Benzinga
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
From Cassava Sciences, Inc.
Via GlobeNewswire
Snowflake (SNOW) Stock Is Sliding Despite AI Hopes
Snowflake (SNOW) stock is on the move Thursday following the release of the company's second-quarter earnings report for fiscal 2024. 
Via InvestorPlace
Topics Artificial Intelligence
Is Splunk (SPLK) Stock the Next AI Giant?
Splunk (SPLK) stock climbed higher on Thursday as investors weighed the company's value in the AI market following its earnings report. 
Via InvestorPlace
Topics Artificial Intelligence
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5% 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During the Friday's sesion, 157 stocks hit new 52-week lows. 
Via Benzinga
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
These three worst biotech stocks are not investable even if you're bullish on the sector overall. There are better options. 
Via InvestorPlace
7 Biotech Stocks to Sell in July
Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July. 
Via InvestorPlace
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
Stock Market Round-Up: Rivian Rides High, Meta Platforms Makes Moves, And Tesla Ticks Up
 
Via Benzinga
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its Phase 3 clinical trials for its Alzheimer's treatment. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Dow, S&P 500 Move Lower On Renewed Fed Fatigue
Stocks are moving lower ahead of the Federal Reserve's June meeting minutes, which are due out this afternoon. 
Via Talk Markets
Promising Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study
Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus... 
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.